hydroxychloroquine has been researched along with Dyslipidemia in 13 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of atorvastatin + hydroxychloroquine fixed-dose combination tablets in comparison with atorvastatin alone in treatment of dyslipidemia." | 9.20 | Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. ( Agarwal, M; Agrawal, N; Chandurkar, N; Dhruv, U; Khyalappa, R; Legha, R; Mathur, SL; Pai, V; Pareek, A; Parmar, M; Pednekar, S; Salkar, HR; Saxena, S; Sriram, U; Thulaseedharan, NK, 2015) |
| "To evaluate the efficacy and safety of atorvastatin + hydroxychloroquine fixed-dose combination tablets in comparison with atorvastatin alone in treatment of dyslipidemia." | 5.20 | Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. ( Agarwal, M; Agrawal, N; Chandurkar, N; Dhruv, U; Khyalappa, R; Legha, R; Mathur, SL; Pai, V; Pareek, A; Parmar, M; Pednekar, S; Salkar, HR; Saxena, S; Sriram, U; Thulaseedharan, NK, 2015) |
| " Secondary outcomes were duration of hospital stay, length of intensive care unit stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects, and complications during the hospitalization." | 2.94 | A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. ( Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS, 2020) |
| "Dyslipidemia is a common disorder in systemic lupus erythematosus (SLE) patients." | 2.61 | Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. ( Chen, T; Cheng, GY; Jiang, YM; Liu, D; Shang, J; Tao, CY; Xiao, J; Yu, D; Zhao, ZZ, 2019) |
| "Hydroxychloroquine, a common treatment for SLE, can improve lipid profiles and should be considered for all patients with SLE." | 2.44 | Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. ( Ardoin, SP; Sandborg, C; Schanberg, LE, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, M | 1 |
| Kumar, M | 1 |
| Dutta, D | 1 |
| Davoudi-Monfared, E | 1 |
| Rahmani, H | 1 |
| Khalili, H | 1 |
| Hajiabdolbaghi, M | 1 |
| Salehi, M | 1 |
| Abbasian, L | 1 |
| Kazemzadeh, H | 1 |
| Yekaninejad, MS | 1 |
| Santos, CS | 1 |
| Morales, CM | 1 |
| Álvarez, ED | 1 |
| Castro, CÁ | 1 |
| Robles, AL | 1 |
| Sandoval, TP | 1 |
| Grewal, SK | 1 |
| Rubin, C | 1 |
| Rosenbach, M | 1 |
| Tao, CY | 1 |
| Shang, J | 1 |
| Chen, T | 1 |
| Yu, D | 1 |
| Jiang, YM | 1 |
| Liu, D | 1 |
| Cheng, GY | 1 |
| Xiao, J | 1 |
| Zhao, ZZ | 1 |
| Migkos, MP | 1 |
| Markatseli, TE | 1 |
| Iliou, C | 1 |
| Voulgari, PV | 1 |
| Drosos, AA | 1 |
| Pareek, A | 2 |
| Chandurkar, N | 2 |
| Thulaseedharan, NK | 1 |
| Legha, R | 1 |
| Agarwal, M | 1 |
| Mathur, SL | 1 |
| Salkar, HR | 1 |
| Pednekar, S | 1 |
| Pai, V | 1 |
| Sriram, U | 1 |
| Khyalappa, R | 1 |
| Parmar, M | 1 |
| Agrawal, N | 1 |
| Dhruv, U | 1 |
| Saxena, S | 1 |
| Luthra, A | 2 |
| Misra, A | 2 |
| Mudur, G | 1 |
| Jain, M | 1 |
| Jani, RH | 1 |
| Ardoin, SP | 1 |
| Sandborg, C | 1 |
| Schanberg, LE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Berberine on the Secretion of Incretin in Normal Man[NCT05947370] | Early Phase 1 | 16 participants (Actual) | Interventional | 2022-10-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxychloroquine and Dyslipidemia
| Article | Year |
|---|---|
Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis.
Topics: Adult; Antimalarials; Chloroquine; Dyslipidemias; Female; Humans; Hydroxychloroquine; Lipids; Lupus | 2019 |
Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.
Topics: Adolescent; Bile Acids and Salts; Child; Complementary Therapies; Dyslipidemias; Humans; Hydroxychlo | 2007 |
2 trials available for hydroxychloroquine and Dyslipidemia
| Article | Year |
|---|---|
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbi | 2020 |
Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Ch | 2015 |
9 other studies available for hydroxychloroquine and Dyslipidemia
| Article | Year |
|---|---|
Hydroxychloroquine in diabetes and dyslipidaemia: primum non nocere.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Enzyme Inhibitors; Human | 2020 |
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiv | 2020 |
Antimalarial therapy for granuloma annulare: Results of a retrospective analysis.
Topics: Adult; Aged; Antimalarials; Dermatologic Agents; Diabetes Complications; Dyslipidemias; Female; Gluc | 2017 |
Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome.
Topics: Aged; Antirheumatic Agents; Atherosclerosis; Dyslipidemias; Female; Humans; Hydroxychloroquine; Lipi | 2014 |
The marketing of unproven drugs for diabetes and dyslipidaemia in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2015 |
Indian endocrinologists start debate on diabetes drug.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2015 |
Drug approvals in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2016 |
Drug approvals in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2016 |
Drug approvals in India - Authors' reply.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2016 |